Salonpas (methyl salicylate) is a small molecule pharmaceutical. Methyl salicylate was first approved as Salonpas on 2008-02-20. It is used to treat acute pain, arthritis, back pain, contusions, and inflammation amongst others in the USA. It is known to target transient receptor potential cation channel subfamily A member 1. Tri-luma's patent is valid until 2030-01-03 (FDA).
|Common Name||Methyl salicylate|
|Indication||acute pain, arthritis, back pain, contusions, inflammation, muscle cramp, sprains and strains|
|Drug Class||Anti-inflammatory agents (salicylic acid derivatives)|